Jacobio Pharmaceuticals (HKG:1167) said its indirect subsidiary, Beijing Jacobio, has received an upfront payment of 125 million yuan from Oceanpine Capital under previously announced capital increase and equity transfer agreements, according to a Tuesday Hong Kong bourse filing.
Shares of the firm were down nearly 3% in Wednesday morning trade.
The company said the funds will strengthen its cash position and support the development of its oncology drug pipeline.